Abbott Laboratories (ABT) has witnessed different activities in the recent period that includes stock shares bought by various investors and asset management firms, such as
Tredje AP fonden, Siligmueller & Norvid Wealth Advisors LLC, Raiffeisen Bank International AG, Vanguard Group Inc., and Southeast Asset Advisors LLC. The company's stock has faced a descent, with shares down 16% from its 52-week high. ABT's CEO has bet $2M as the stock sinks. Despite the dip, there is a significant buy sentiment among investors. Promising results have been announced for
Amulet 360 Left Atrial Appendage (LAA) Occluder. Moreover, ABT has recently announced the acquisition of
Exact Sciences. Although the company faced a lackluster Q4 2025 performance with missed revenue estimates resulting in decline in its shares, organic sales growth is expected in 2026 and the fundamentals of ABT remain strong, suggesting that market weakness could be providing a buying opportunity. Lastly, the company's strong financial prospects are considered attractive by market analysts, making it a good option for long-term investors, especially since it's a dividend stock.
Abbott Laboratories ABT News Analytics from Thu, 17 Jul 2025 07:00:00 GMT to Sat, 21 Feb 2026 14:15:01 GMT -
Rating 2
- Innovation 4
- Information 6
- Rumor -3
